

Noncompacted Ventricular Myocardium: Is Syncope the Only Warning Sign?

Trieu Q. Ho, MD, Daniel J. Lenihan, MD, Bharat K. Kantharia, MD and Anne H. Dougherty, MD

Abstract: We present a case of a 14-year-old young boy with ventricular noncompaction and coexistent Wolff-Parkinson-White syndrome who presented with syncope. Detailed testing was performed, and an ablation was successful for Wolff-Parkinson-White syndrome; however, because of patient/family desires, an implantable cardioverter-defibrillator was placed. A careful review of the literature highlights the complex decision making involved with this condition.

Key Indexing Terms: Wolff-Parkinson-White syndrome; Isolated noncompaction of the ventricular myocardium; Cardiomyopathy. [*Am J Med Sci* 2010;339(5):497–500.]

Although the incidence of isolated noncompacted ventricular myocardium remains unknown, awareness of this entity has become increasingly widespread, largely because of improved imaging and identification of this cardiomyopathy. Noncompaction of the ventricular myocardium is characterized by prominent trabeculation of the left ventricular (LV) (and potentially the right myocardium) thought to result from incomplete embryogenesis. Thus, there can be associated congenital cardiac defects and neuromuscular disorders.^{1,2} Clinically, these patients are primarily at risk for heart failure, arrhythmias, and serious thromboembolic events. In fact, electrocardiographic abnormalities are common including Wolff-Parkinson-White syndrome (WPW).^{3–5} The incidence of WPW syndrome varies from different reports, but the incidence of WPW syndrome (15%) is higher in children with noncompaction.⁶ The incidence of sudden death is not known but certainly increased compared with that expected for a matched population.

Herein, we report a young patient with ventricular noncompaction and WPW syndrome who presented with syncope. A careful review of the literature illustrates some of the difficult decision making required for this newly described condition.²

CASE REPORTS

A 14-year-old African American boy, a previously healthy adolescent, was admitted to Memorial Hermann Hospital with the first episode of syncope that occurred while running. The patient did not have any chest pain, palpitations, dyspnea, lightheadedness, or dizziness before his syncope. He had no family history of sudden cardiac death (SCD) or syncope nor was there any early heart disease in primary family members. He was on no medications and had no significant medical history. On presentation, his pulse was 70 beats per minute (bpm), blood pressure was 108/70 mm Hg, and his

respirations were 16/min. He was afebrile; he was not orthostatic. He was alert and oriented with some superficial abrasions over his left forehead and left arm. His cardiac examination was unremarkable. His baseline laboratory examination was normal. His baseline electrocardiogram (ECG) is shown in Figure 1.

His ECG revealed sinus rhythm with heart rate of 66 bpm, with a PR interval of 80 milliseconds, and an apparent delta wave consistent with an accessory pathway diagnostic of WPW syndrome. Based on surface ECG, the accessory pathway is characterized as a posterior pathway. The 24-hour Holter monitor indicated only sinus rhythm, with rates of 53 to 134 bpm with a mean rate of 75 bpm. The heart rate responses to reported activity were appropriate. Normal diurnal variations in heart rates were observed. Preexcitation was consistently present with short PR interval and a permanent delta wave. A 2D echocardiogram revealed normal LV function with multiple thickened LV trabeculations consistent with ventricular noncompaction. Subsequent magnetic resonance imaging provided further detail demonstrating LV hypertrophy and numerous pronounced trabeculations (Figure 2). There was no evidence of LV thrombus. Because of the patient's presentation with syncope, an electrophysiologic study was performed with successful ablation of the accessory pathway.

At baseline, the rhythm was sinus with preexcitation, and the characteristics of the pathway were considered marginal risk, and no supraventricular or ventricular tachycardia was induced. Accessory pathway could not be demonstrated at the completion of the study. The postablation ECG is shown in Figure 3. An extensive discussion with the patient, his family, and all involved providers was then undertaken to describe the outcomes of patients with ventricular noncompaction and how it applies to this exact case. Ultimately, the decision to proceed with an implantable cardioverter-defibrillator (ICD) was agreed on and successfully placed via the left subclavian vein. The patient recovered uneventfully and has been placed on long-term anticoagulation. He has been asymptomatic since his initial admission.

DISCUSSION

This case highlights many of the complex decisions that may be encountered when a patient is diagnosed with ventricular noncompaction. Although isolated LV noncompaction was first described in 1984,⁷ recent increased imaging and awareness has resulted in this entity being recognized by a host of medical societies as a genetic cardiomyopathy.^{8,9} However, ventricular noncompaction remains as an unclassified cardiomyopathy according to the World Health Organization.¹⁰ More importantly, ventricular noncompaction has become an important entity to consider when diagnosing and managing cardiomyopathy. Ventricular noncompaction is in a broad population of patients characterized by excessively prominent trabeculations and deep intertrabecular recesses in the left ventricle without other congenital cardiac abnormalities.³ In normal

From the Division of Cardiology (TQH, BKK, AD), The University of Texas Health Science Center, Houston, Texas; and Department of Cardiology (DJL), The University of Texas M.D. Anderson Cancer Center, Houston, Texas.

Submitted January 20, 2010; accepted in revised form February 10, 2010.

Correspondence: Anne H. Dougherty, MD, Division of Cardiology, The University of Texas Medical School at Houston, MSB 1.246, 6431 Fannin, Houston, TX 77030 (E-mail: anne.h.dougherty@uth.tmc.edu).




FIGURE 1. ECG at baseline. Solid arrow shows delta wave. Dashed arrow shows short PR interval. ECG, electrocardiogram.

developmental process, the direct continuity between the atrial and ventricular myocardium is lost when the annulus fibrosus forms.¹¹ The basic morphogenic abnormalities of ventricular noncompaction are thought to be caused by the arrest of the normal process of compaction and normal process of development of the annulus fibrosus.³ Interestingly, the defects in annulus fibrosus may allow the formation of the accessory pathways.¹² As a result, ventricular noncompaction has been

associated with multiple abnormal ECG patterns typically associated with accessory pathways such as WPW, left bundle branch block, left axis deviation, and other arrhythmias including atrial fibrillation.³⁻⁵ In fact, the most frequent clinical manifestations of symptomatic patients with ventricular noncompaction are ventricular arrhythmias, heart failure, and systemic embolizations,^{3,4,13-15} which accounts for excess mortality and morbidity associated with this condition. Thromboembolic events




FIGURE 2. Magnetic resonance imaging (MRI) in a patient with ventricular noncompaction. Short axis (A), longitudinal (B) images, and sagittal MRI images (C) showing no thrombus but increased trabeculation of the left ventricle (white arrows).




FIGURE 3. Postablation ECG. The arrow indicates the absence of the previously evident delta wave. ECG, electrocardiogram.

have been seen in young patients with sinus rhythm and normal LV function,¹⁶ and most expert opinions recommend long-term anticoagulation to all patients with ventricular noncompaction.^{4,14,16–19} Our patient has been placed on long-term anticoagulation therapy to prevent an increased incidence of cerebrovascular and other systemic emboli that has been observed in this population.

The etiology of ventricular arrhythmia in ventricular noncompaction has not been fully elucidated. It seems that ventricular arrhythmia is one of the most important causes of SCD in these patients. Placement of an ICD seems to be an effective form of therapy in these patients while cardiac transplantation may also have a role in therapy.^{3,4,6,20} Although our patient had normal LV systolic function, an elective ICD was placed as fatal arrhythmia has occurred in patients with normal systolic function, depressed systolic function, or impairment of LV function.^{4,21,22} In addition, despite our successful ablation of the right posterior paraseptal accessory pathway, we could not be confident that the ablation by itself was sufficient to prevent this patient from future syncope episodes or SCD because of fatal ventricular arrhythmia.

Ventricular noncompaction is a rare genetically heterogeneous disorder for which the true prevalence is unknown. In 1 large series, it is suggested that the prevalence of ventricular noncompaction by echocardiography in adults is approximately 0.014%.² The rate of familial recurrence is reported to be 18% to 25%, with predominately autosomal dominant inheritance.² There are few cases reported of X-linked and mitochondrial inheritance.² Mutations in the gene encoding for α dystrobrevin, G 4.5, and LIM domain binding protein 3 have all been implicated in the development of ventricular noncompaction.^{23–26} Furthermore, there are a number of gene mutations in mice (eg, *FKBP12*), which cause noncompaction of the ventricular myocardium.²⁷ However, in a recent study using a large cohort of patients with ventricular noncompaction, the preva-

lence of these mutations is low, indicating that the genetic basis of the disease is yet to be uncovered²⁴ and the ability of genetic analysis in this disease is not established.

In conclusion, this case study highlights much of the complex decision making that may be required to optimally manage a patient with ventricular noncompaction. It is likely that this condition will be recognized with increasing frequency because of the increased availability of cardiac imaging including screening young adults and those participating in competitive athletics. Thus, a review of available data and recognition of associate cardiac risks will be of crucial importance. Until more definitive information becomes available, consideration for placement of an ICD and long-term anticoagulation should be prominent in clinical decision making for those patients.

REFERENCES

1. Stollberger C, Kopsa W, Tscherny R, et al. Diagnosing left ventricular noncompaction by echocardiography and cardiac magnetic resonance imaging and its dependency on neuromuscular disorders. *Clin Cardiol* 2008;31:383–7.
2. Weiford BC, Subbarao VD, Mulhern KM. Noncompaction of the ventricular myocardium. *Circulation* 2004;109:2965–71.
3. Chin TK, Perloff JK, Williams RG, et al. Isolated noncompaction of left ventricular myocardium. A study of eight cases. *Circulation* 1990; 82:507–13.
4. Ritter M, Oechslin E, Sutsch G, et al. Isolated noncompaction of the myocardium in adults. *Mayo Clin Proc* 1997;72:26–31.
5. Robida A, Hajar HA. Ventricular conduction defect in isolated noncompaction of the ventricular myocardium. *Pediatr Cardiol* 1996;17: 189–91.
6. Ichida F, Hamamichi Y, Miyawaki T, et al. Clinical features of isolated noncompaction of the ventricular myocardium: long-term clinical course, hemodynamic properties, and genetic background. *J Am Coll Cardiol* 1999;34:233–40.

7. **Engberding R, Bender F.** Identification of a rare congenital anomaly of the myocardium by two-dimensional echocardiography: persistence of isolated myocardial sinusoids. *Am J Cardiol* 1984;53:1733-4.
8. **Maron BJ, Towbin JA, Thiene G, et al.** Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. *Circulation* 2006;113:1807-16.
9. **Thiene G, Corrado D, Basso C.** Cardiomyopathies: is it time for a molecular classification? *Eur Heart J* 2004;25:1772-5.
10. **Richardson P, McKenna W, Bristow M, et al.** Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. *Circulation* 1996;93:841-2.
11. **Dunnigan A.** Developmental aspects and natural history of preexcitation syndromes. In: Benditt DG, Benson DW, editors. *Cardiac preexcitation syndromes: origins, evaluation, and treatment*. Boston (MA): Nijhoff; 1986. p. 21-9.
12. **Lunel AA.** Significance of annulus fibrosus of heart in relation to AV conduction and ventricular activation in cases of Wolff-Parkinson-White syndrome. *Br Heart J* 1972;34:1263-71.
13. **Lin ML, Connelly K, Prior D.** An unusual cause of heart failure identified by echocardiography in an octogenarian. *Eur J Heart Fail* 2005;7:99-102.
14. **Oechslin EN, Attenhofer Jost CH, Rojas JR, et al.** Long-term follow-up of 34 adults with isolated left ventricular noncompaction: a distinct cardiomyopathy with poor prognosis. *J Am Coll Cardiol* 2000;36:493-500.
15. **Taniguchi M, Hioka T, Maekawa K, et al.** Adult case of isolated ventricular noncompaction discovered by complete atrioventricular block. *Circ J* 2004;68:873-5.
16. **Murphy RT, Thaman R, Blanes JG, et al.** Natural history and familial characteristics of isolated left ventricular non-compaction. *Eur Heart J* 2005;26:187-92.
17. **Borges AC, Kivelitz D, Baumann G.** Isolated left ventricular non-compaction: cardiomyopathy with homogeneous transmural and heterogeneous segmental perfusion. *Heart* 2003;89:e21.
18. **Tong KL, Ding ZP.** Isolated non-compaction of ventricular myocardium: a report of three cases. *Ann Acad Med Singapore* 2001;30:539-41.
19. **Blessing E, Rottbauer W, Mereles D, et al.** Isolated left ventricular noncompaction of the myocardium as a cause of embolic superior mesenteric artery occlusion. *J Am Soc Echocardiogr* 2005;18:693.
20. **Silka MJ, Kron J, Dunnigan A, et al.** Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. *The Pediatric Electrophysiology Society. Circulation* 1993;87:800-7.
21. **Buonanno C, Variola A, Dander B, et al.** Isolated noncompaction of the myocardium: an exceedingly rare cardiomyopathy. A case report. *Ital Heart J* 2000;1:301-5.
22. **Yasukawa K, Terai M, Honda A, et al.** Isolated noncompaction of ventricular myocardium associated with fatal ventricular fibrillation. *Pediatr Cardiol* 2001;22:512-4.
23. **Chen R, Tsuji T, Ichida F, et al.** Mutation analysis of the G4.5 gene in patients with isolated left ventricular noncompaction. *Mol Genet Metab* 2002;77:319-25.
24. **Ichida F, Tsubata S, Bowles KR, et al.** Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. *Circulation* 2001;103:1256-63.
25. **Kenton AB, Sanchez X, Coveler KJ, et al.** Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12. *Mol Genet Metab* 2004;82:162-6.
26. **Vatta M, Mohapatra B, Jimenez S, et al.** Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. *J Am Coll Cardiol* 2003;42:2014-27.
27. **Shou W, Aghdasi B, Armstrong DL, et al.** Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. *Nature* 1998;391:489-92.